Finn Edler von Eyben, M.D., Ph.D.

Finn Edler von Eyben, M.D.

Center of Tobacco Control Research, Odense, Denmark

  • Biography
  • Research Interests
  • Publications

Dr Finn Edler von Eyben is a specialist in oncology and internal medicine. He has worked full time as physician for more than 35 years. He has worked as consultant in internal medicine and oncology. He has worked in 3 Scandinavian countries and in the United Arab Emirates and Greenland. He is the corresponding author of more than 100 original articles and letters to the editor in national and international peer-reviewed journals and has contributed as co-author to further 40 publications.

Dr von Eyben was the first oncologist to describe serum lactate dehydrogenase as a prognostic factor for testicular germ cell tumors (TGCT). The finding is included in the TNM classification. In addition, he described microinvasive germ cell tumor of the testis (MGCT) as an intermediate precursor stage in the development of TGCT. Furthermore, he was the first to describe an ophthalmologic complication from Tamoxifen and established mitotane as a porphyrogen for porphyria. He is the first author of 3 published original articles and 1 commentary on prostate cancer.

Dr von Eyben added to the evidence that cigarette smoking was a highly significant and the main modifiable cardiovascular risk factor for acute myocardial infarction for young subjects less than 40 years of age. He has defended a thesis at the University of Lund, Sweden, in 1983, and a thesis at Southern Danish University in 2005. Dr von Eyben has published two books, one on testicular germ cell tumors and one on smoking cessation.

He has many commentaries on the relative short Danish median life expectancy and state regulation of smoking in newspapers, radio, and TV. In 1980,  he wrote a protocol for interferon treatment of malignant melanoma, that was used as the base for the confirmatory studies in the thesis of Per Flodgren in Sweden. He wrote a pamphlet –  the smoke-free Denmark year 2000. He has obtained grants for research on the impact on survival from the legal castration of men and on precursor stages of testicular germ cell neoplasms.

Cancer imaging, cardiovascular risk factors, diagnostic test accuracy, endocrinology, meta analysis, prostate cancer, public health, quality assurance, smoking prevention, testicular germ cell tumors and tumor markers. Research on the clinical aspects of imaging of prostate cancer.

  1. von Eyben FE, Larsen V, Pedersen H. 5-fluorouracil (NSC-19893), DTIC (NSC-45388), BCNU (NSC-409962), and vincristine (NSC-67574) in advanced colorectal carcinoma. Cancer Treat Rep 1976;60:29-32.
  2. Mattsson W, Arwidi A, von Eyben F, Lindholm CE. Phase II study of combined vincristine, adriamycin, cyclophosphamide, and methotrexate with citrovorum rescue in metastatic breast cancer. Cancer Treat Rep 1977;61:1527-1531.
  3. Mattsson W, von Eyben F, Turesson I, Wahlby S. Prednimustine (NSC-134087, Leo 1031) treatment of lymphocytic and lymphocytic-histiocytic lymphomas. Cancer 1978;41:112-116.
  4. von Eyben FE. Biochemical markers in advanced testicular tumors. Serum lactate dehydrogenase, urinary chorionic gonadotropin and total urinary estrogens. Cancer 1978;41:648-652.
  5. von Eyben F, Olsen TS. Cytomegalovirus pneumonia after treatment with melphalan and prednisone. Report of a case. Acta Med Scand 1978;203:333-335.
  6. von Eyben FE, Mattsson W, Trope C. Phase II study of Prednimustine (NSC-134087, EORTC 1502) in advanced lymphocytic and lymphocytic-histiocytic lymphomas. Current chemotherapy. Proc 10 Int Congress   Chemotherapy 1978;II:1273-1274.
  7. von Eyben F, Mattsson W, Glifberg I, Lindholm CE. Chemotherapy of advanced transitional cell carcinoma of the renal pelvis: Report of 3 cases treated with vinblastine and chloroethyl-cyclohexyl-nitrosourea. J Urol 1979;121:367-368.
  8. Mattsson W, Arwidi A, von Eyben F, Lindholm CE. Combination chemotherapy in advanced postmenopausal mammary carcinoma. A comparison between VAC and VACM therapy. Acta Radiol Oncol Radiat Phys Biol 1979;18:431-444.
  9. Krabbe S, Skakkebaek NE, Berthelsen JG, Eyben FV, Volsted P, Mauritzen K, Eldrup P, Nielsen AH. High incidence of undetected neoplasia in maldescended testes. Lancet 1979;1:999-1000.
  10. von Eyben FE, Bruze M, Eksborg S, Mattsson W, Jonsson K. Toxic epidermal injury following intraarterial adriamycin treatment. Cancer 1981;48:1535-1538.
  11. von Eyben F, Mikulowski P, Busch C. Microinvasive germ cell tumors of the testis. J Urol 1981;126:842-844.
  12. von Eyben F, Krabbe S, Skakkebaek NE. Alpha-foetoprotein and human chorionic gonadotropin in men with maldescended testes. Br J Cancer 1980;42:156-157.
  13. von Eyben F, Hellekant C, Mattsson W, Ljungquist U,Jonsson K. Mitomycin C in advanced gallbladder carcinoma. Acta Radiol Oncol 1981;19:81-84.
  14. von Eyben FE, Tropé C, Ljungberg O, Alm P, Wennerberg J, Gullberg B. Histologic pattern and growth in two human testis cancers before and after transplantation to nude mice. Cancer 1982;50:2845-2853.
  15. Mattsson W, von Eyben F, Hallsten L, Bjelkengren G. A phase II study of combined 5-fluorouracil and mitomycin C in advanced breast cancer. Cancer 1982;49:217-220.
  16. von Eyben FE, Arwidi A, Hellekant C, Jonsson K, Lindahl SA, Mattsson W, Tennvall L. Vincristine, adriamycin, cyclophosphamide and etoposide (VP 16-213) in small-cell anaplastic carcinoma of the lung. Cancer Chemother Pharmacol 1982;7:195-197.
  17. von Eyben FE. Phase II study of vindesine in patients with advanced breast carcinoma. Drugs Exptl Clin Res 1982;8:547-551.
  18. Tropé C, Wennerberg J, Alm P, von Eyben FE. Heterotransplantation of two human tumours in nude and asplenic-athymic mice. Acta Pathol Microbiol Immunol Scand A 1982;90:75-77.
  19. Mattsson W, von Eyben F, Hallsten L, Tennvall L. A trial of tamoxifen versus high-dose medroxyprogesterone acetate in advanced postmenopausal breast cancer. A final report. Excerpta Med Proc Int Symp   Medroxyprogesterone Acetate, Geneva, Switzerland, February 24-26, 1982, Cavalli F, McGuire WL, Panutti F, Pellegrini A, Robustelli Della Guna G,eds, 1982;276-284.
  20. von Eyben FE, Skude G, Krabbe S. Serum lactate dehydrogenase and its isoenzymes in men with maldescended testes. J Urol 1982;128:1195-1197.
  21. von Eyben FE, Skude G, Tropé C, Wennerberg J, Mikulowski P. Lactate dehydrogenase isoenzyme 1 (LDH-1) in athymic mice with xenografts of a human testicular germ cell tumor. Mol Gen Genet 1982;186:427-431.
  22. Berglund S, Eriksson M, von Eyben FE, Hellekant C, Mattsson W. Remission by chemotherapy of the Eaton-Lambert myasthenic syndrome in a patient with small cell bronchogenic carcinoma. Acta Med Scand 1982;212:429-432.
  23. von Eyben FE, Jacobsen GK, Pedersen H, Jacobsen M, Clausen PP, Zibrandtsen PC, Gullberg B. Multivariate analysis of risk factors in patients with metastatic testicular germ cell tumors treated with vinblastine and bleomycin. Invasion Metastasis 1982;2:125-135.
  24. Borgström S, von Eyben FE, Flodgren P, Axelsson B, Sjögren HO. Human leukocyte interferon and cimetidine for metastatic melanoma. N Engl J Med 1982;307:1080-1081.
  25. von Eyben FE. Lactate dehydrogenase and its isoenzymes in testicular germ cell tumors: an overview. Oncodev Biol Med 1983;4:395-414.
  26. von Eyben FE, Skude G, Fosså SD, Klepp O, Børmer O. Serum lactate dehydrogenase (S-LDH) and S-LDH isoenzymes in patients with testicular germ cell tumors. Mol Gen Genet 1983;189:326-333.
  27. von Eyben FE, Arends J. Suppression of the mitogen response of normal lymphocytes by serum from patients with testicular germ cell tumors. Am J Reprod Immunol 1983;4:5-10.
  28. Flodgren P, Borgström S, von Eyben FE, Ingvar C, Jonsson PE, Malmström A, Axelsson B, Sjögren HO. Metastatic malignant melanoma: regression induced by combined treatment with interferon (HUINF-alpha(Le))and cimetidine. In: De Mayer E et al, eds.: The biology of the interferon system, 1983, TNO Congress, Rotterdam, The Netherlands 4/18-4/22 1983:499-504.
  29. Skude G, von Eyben FE, Kristiansen P. Additional lactate dehydrogenase (LDH) isoenzymes in normal testis and spermatozoa of adult man. Mol Gen Genet 1984;198:172-174.
  30. von Eyben FE, Grann E, Dyrlund B. Xanthopsia treated with thiamine. Acta Ophthalmol 1985;63:591-592.
  31. von Eyben FE, Szpirt W. Pneumococcal sepsis with hemolytic-uremic syndrome in the adult. Nephron 1985;40:501-502.
  32. Pugesgaard T, von Eyben FE. Bilateral optic neuritis evolved during tamoxifen treatment. Cancer 1986;58:383-386.
  33. von Eyben FE, Hoyer PE, Busch C. Microspectrophotometric observations of a microinvasive testicular germ cell tumor. In: Jones WG, Ward AM, Andersson CK, eds: Germ Cell Tumours II, Adv Biosci 1986;55:57-58.
  34. Hansen SB, Galsgård H, von Eyben FE, Westergaard-Nielsen V, Wolf-Jensen J. Tamoxifen for brain metastases from breast cancer. Ann Neurol 1986;20:544.
  35. von Eyben FE, Siddiqui MZ, Spanos G. High-voltage irradiation and hydroxyurea for pulmonary leukostasis in acute myelomonocytic leukemia. Acta Haematol 1987;77:180-182.
  36. von Eyben FE, Blaabjerg O, Petersen PH, Hørder M, Nielsen HV, Kruse-Andersen S, Parlev E. Lactate dehydrogenase isoenzyme 1 in testis cancer. Lancet 1987;ii:1035-1036.
  37. Siddiqui MZ, von Eyben FE, Spanos G. High-voltage irradiation and combination chemotherapy for malignant pheochromocytoma. Cancer 1988;62:686-690.
  38. von Eyben FE, Blaabjerg O, Petersen PH, Hørder M, Nielsen HV, Kruse-Andersen S, Parlev E. Serum lactate dehydrogenase isoenzyme as tumor marker in testicular germ cell tumor. J Urol 1988;140:986-990.
  39. Thunold S, von Eyben FE, Maehle B. Malignant granular cell tumour of the neck: immunohistochemical and ultrastructural studies of a case. Histopathology 1989;14:655-657.
  40. von Eyben FE, Siddiqui MZ, Thunold S. Endodermal sinus tumor treated with high dose cisplatin. Acta Obstet Gynecol Scand 1989;68:669-670.
  41. Marckmann P, Højbjerg T, von Eyben FE, Christensen I.Imported pedal chancroid: case report. Genitourin Med 1989;65:126-127.
  42. Pors H, von Eyben FE, Sørensen O, Larsen M. Longterm remission of multiple brain metastases with tamoxifen. J Neurooncol 1991;10:173-177.
  43. von Eyben FE, Grodum E, Gjessing HJ, Hagen C, Nielsen H. Metabolic remission with octreotide in patients with insulinoma. J Int Med 1994;235:245-248.
  44. von Eyben FE, Blaabjerg O, Petersen PH, Mommsen S, Lindegaard-Madsen E, Kirkepar F, Li S-L, Kristiansen K. Lactate dehydrogenase isoenzyme 1 in testicular germ cell tumors. Recent Results in Cancer Research 1991;123:85-92.
  45. Ellekilde G, von Eyben FE, Holm J, Hemmingsen L. Above-normal urinary excretion of retinol-binding protein and microalbuminuria in albustix-negative hypertensive patients. Clin Chem 1991;37:1446-1447.
  46. von Eyben FE, Blaabjerg O, Madsen EL, Petersen PH, Smith-Sivertsen C, Gullberg B. Serum lactate dehydrogenase isoenzyme 1 and tumour volume are indicators of response to treatment and predictors of prognosis in advanced testicular germ cell tumours. Eur J Cancer 1992;28:410-415.
  47. von Eyben FE, de Graaff WE, Marrink J, Blaabjerg O, Sleijfer DT, Koops HS, Oosterhuis JW,Petersen PH, van-Echten Arends J, de Jong B. Serum lactate dehydrogenase isoenzyme 1 activity in patients with testicular germ cell tumors correlates with the total number of the short arm of chromosome 12 in the tumor. Mol Gen Genet 1992;235:140-146.
  48. Ellekilde G, Holm J, von Eyben F, Hemmingsen L. Above-normal urinary excretion of albumin and retinol- binding protein in chronic heart failure. Clin Chem 1992;38:593-594.
  49. Ellekilde G, Holm J, Hemmingsen L. Koczulab B, von Eyben FE. Impact of angiotensin-converting enzymes on urinary excretion of proteins in chronic heart failure. Clin Chem 1992;38:1377-1378.
  50. Hansen EF, Andersen LT, von Eyben FE. Cigarette smoking and age at first acute myocardial infarction and influence of gender and extent of smoking. Am J Cardiol 1993;71:1439-1442.
  51. von Eyben FE, Petersen PH, Blaabjerg O, Lindegaard Madsen E, Nørgaard Petersen B, Arends J. Correcting for contamination from hemolysis in measurements of lactate dehydrogenase isoenzyme 1 in serum from patients with testicular germ cell tumors.   Clin Chem 1993;39:2199.
  52. von Eyben FE, Petersen PH, Blaabjerg O, Madsen EL, Nørgaard-Pedersen B, Arends J. Analytical bias by contamination from hemolysis in determination of serum lactate dehydrogenase isoenzyme 1 in patients with testis germ cell tumors. Upsala J Med Sci 1993;98:293-298.
  53. Ellekilde G, von Eyben FE, Holm J, Hemmingsen L. Above-normal urinary excretion of albumin and retinol-binding protein for patients with acute myocardial infarction. Clin Chem 1993;39:2350-2351.
  54. Ellekilde G, von Eyben FE, Holm J, Hemmingsen L. Above-normal urinary excretion of albumin and retinol-binding protein for patients with acute myocardial infarction. Clin Chem 1993;39:2535-2351.
  55. Børger J, Zachau-Christensen J, von Eyben FE. Patient awareness of medication. J Danish Health Organisation 1994;9:382-385.
  56. von Eyben FE, Heerfordt J, Lassen JO, Jørgensen HP. Computer tomography in Greenland – a basis for establishment of service. Ugeskr Laeger 1994;156:4589-4591.
  57. von Eyben FE. Planning arctic secondary and tertiary health care service. Congress book, IX Int Conf Circumpolar Health, Reykjavik, Iceland,1994.
  58. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-685.
  59. von Eyben FE, Lindegaard Madsen E, Blaabjerg O, Petersen PH. Lactate hydrogenase isoenzyme 1. An early indicator of relapse in patients with testicular germ cell tumors. Acta Oncol 1995;34:925-929.
  60. von Eyben FE, Bech J, Kyst Madsen J, Efsen F. High prevalence of smoking in young patients with acute myocardial infarction. J R Soc Health 1996;116:153-156.
  61. von Eyben FE, Lindegaard Madsen E. Serum lactate dehydrogenase isoenzyme 1 as predictor of tumour-associated death in patients with testicular germ cell tumours. andrologia 1997;29:137-140.
  62. Byrialsen A, von Eyben FE, Kristiansen K. Carcinoma in situ of the testis and seminoma have high protein levels of lactate dehydrogenase (LD) subunit B and no LD subunit C. J Tumor Marker Oncol 1998;13:79-86.
  63. von Eyben FE, Petersen PH, Blaabjerg O, Madsen EL. Analytical goals for monitoring serum lactate dehydrogenase isoenzyme 1 in patients with testicular germ cell tumors. In: Jones WG, Appleyard I, Harnden P, Joffe K, eds. Germ cell tumours. Libbey & Co 1998;111-112.
  64. von Eyben FE, Petersen PH, Blaabjerg O, Madsen EL. Analytical quality specifications for serum lactate dehydrogenase isoenzyme 1 based on clinical Goals. Clin Chem Lab Med 1999;37:553-561.
  65. von Eyben FE, Liu FJ, Amato RJ, Fritsche HA. Serum lactate dehydrogenase isoenzyme 1 is the most important LD isoenzyme in patients with testicular germ cell tumors. Acta Oncol 2000;39:509-517.
  66. von Eyben FE, von Eyben R. Smoking and other modifiable major coronary risk factors and acute myocardial infarction before 41 years of age. Two Danish case-control studies. Scand Cardiovasc J 2001;35:25-29.
  67. von Eyben FE, Madsen EL, Blaabjerg O, Petersen PH, von der Maase H, Jacobsen GK, Rorth M. Serum lactate dehydrogenase isoenzyme 1 and relapse in patients from a randomized DATECA study of nonseminomatous testicular germ cell tumors clinical stage I. Acta Oncol 2001;40:536-540.
  68. von Eyben FE. A systematic review of lactate dehydrogenase isoenzymes as tumor marker of germ cell tumors. Clin Biochem 2001;344:444-454.
  69. von Eyben FE, Blaabjerg O, Petersen PH, Madsen EL, Amato R, Liu F, Fritsche H. Serum lactate dehydrogenase isoenzyme 1 activity in prediction of death for patients with metastatic testicular germ cell tumors. Clin Chem Lab Med 2001:39:38-44.
  70. von Eyben FE, Lindegaard Madsen E, Blaabjerg O, Jacobsen GK, Petersen PH, Pedersen BN, Specht L, von der Maase H. Serum lactate dehydrogenase isoenzyme 1 at orchiectomy in patients with seminoma stage I followed with surveillance. Acta Oncol 2002;41:77-83.
  71. von Eyben FE, Mouritsen E, Holm J, Dimcevski G, Kristensen L, Suciu,G, von Eyben R. Smoking, low density lipoprotein, fibrinogen and myocardial infarction. Before 41 years of age. A Danish case-control study. J Cardiovasc Risk 2002;9:171-178.
  72. von Eyben FE, Holzik ML. Alpha fetoprotein, tumour histology, and copy number of isochromosome i(12p) in testicular germ cell tumours. J Tumor Marker Oncol 2002;17:5-11.
  73. von Eyben FE. Laboratory markers and germ cell tumors. Crit Rev Clin Lab Sci 2003;40:377-427.
  74. von Eyben FE, Madsen EL, Fritsche H, Suciu G, Liu F, Amato R. A new prognostic model for testicular germ cell tumors. APMIS 2003;111:100-105.
  75. von Eyben FE, Mouritsen E, Holm J, Montvilas P, Suciu G, Helleberg I, Kristensen L, von Eyben R. Intra-abdominal obesity and metabolic risk factors: a study of young adults. Int J Obes 2003;27:941-949.
  76. von Eyben FE. Chromosomes, genes, and development of testicular germ cell tumors. Cancer Genet Cytogenet 2004;151:93-138.
  77. von Eyben FE, Mouritsen E, Holm J, Montvilas P, Suciu G, Helleberg I, Kristensen L, von Eyben R. Intraabdominal obesity and metabolic risk factors. Ugeskr Laeger 2004;266:2262-2264.
  78. von Eyben FE, Jacobsen GK, Rorth M, von der Maase H. Microinvasive germ cell tumour (MGCT) adjacent to testicular germ cell tumours. Histopathology 2004;44:547-554.
  79. von Eyben FE, Mouritsen E, Holm J, Montvilas P, Dimcevski G, Suciu G, Rasmussen IH, Kristensen LL, von Eyben R. Plasminogen activator inhibitor 1 activity and other coronary risk factors. Clin Appl Thromb Hemost 2005;11:55-61.
  80. von Eyben FE, Kroustrup JP, Larsen JF, Celis J, Abdominal obesity Study Group. Comparison of gene expression in intra-abdominal and subcutaneous fat: a study of men with morbid obesity and non-obese men using microarray and proteomics. Ann N Y Acad Sci 2004;1030:508-536.
  81. von Eyben FE, Mouritsen EA, Holm J, Montvilas P, Dimcevski G, Rasmussen H, Kristensen IL, von Eyben R. Fibrinogen and other coronary risk factors. Metabolism 2005;39:165-170.
  82. von Eyben, FE, Jacobsen GK, Skotheim R. Microinvasive germ cell tumor of the testis. Virchows Arch 2005;447:610-625.
  83. von Eyben FE, Graugaard C, Vaeth M. All-cause mortality and mortality of myocardial infarction in 989 legally castrated men. Eur J Epidemiol 2005;20:863-869.
  84. Bjerre C, von Eyben. Smoking policy in Ringkoebing county. Chapter in Conference Book, Watch-4, New Delhi, 2005.
  85. von Eyben FE, Mouritsen E, Holm J, Dimcevski G, Montvilas P, Suciu G. Computed tomography scans of intra-abdominal fat, anthropometric measurements and 3 nonobese metabolic risk factors. Metabolism 2006;55:1337-1343.
  86. von Eyben FE. Epidermal growth factor receptor inhibition and non-small cell lung cancer. Crit Rev Clin Lab Sci 2006;43:291-323.
  87. Suacidani P, Hein HH, von Eyben FE, Gyntelberg F. Metabolic and lifestyle predictors of ischemic heart disease and all-cause mortality among normal weight, overweight, and obese men: a 16-year follow-up in the Copenhagen Male Study. Metab Syndr Relat Disord 2009;7:97-104.
  88. von Eyben. Diabetes type 2 – treatment at a local hospital. Indremedisineren 2010;3:18-19.
  89. von Eyben FE. Mitotane as a possible cause of acute intermittent porphyria. Ugeskr Laeger 2011;273:2268-2269.
  90. von Eyben FE, Kangasmaki A, Kiljunen T, Joensuu T. Volumetric-modulated arc therapy for a pelvic lymph-node metastasis from prostate cancer – a case report. Tumori 2013;99.e120-e123.
  91. von Eyben FE, Kairemo K. Meta-analysis of 11C-choline and 18F-choline PET/CT for management of patients with prostate cancer. Nucl Med Com 2014;36:223-230.
  92. von Eyben FE. Quality improvement of metabolic control for patients with type 2 diabetes treated at a general hospital_ a quantitative open cohort study. J Eval Clin Pract 2014;20:429-435.
  93. von Eyben FE,Kairemo K, Kiljunen T, Joensuu T. Planning external beam radiotherapy for prostate cancer guided by PET/CT. Accepted for publication. Current Radiopharmaceuticals, 2014.
  94. von Eyben FE, Jounsuu T, Kangasmaki A, Kairemo K, Kiljunen T. Abiraterone and volumetric modulated arc therapy for second recurrence of node-positive prostate cancer – a case report. J Diagn Imaging Ther 2014; 1(1):73-80.